GlassScriptPhysician profile
Daniel L Neuman
NPI 1437689494
$17,676.75
in general payments reported to CMS, 2019-2025
34 companies · $3,068 in 2025
The $3,068 reported for 2025 was more than what 86% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2021: $1,958 · 2022: $4,467 · 2023: $2,269 · 2024: $5,688 · 2025: $3,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,224 · Travel and Lodging: $1,742 · Entertainment: $59.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,223.86 |
| Travel and Lodging | $1,741.61 |
| Entertainment | $59.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,458.92 | 2021-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $4,256.15 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Nevro Corp. | $1,772.03 | 2019-2024 | Senza |
| Nalu Medical, INC. | $995.39 | 2021-2024 | Nalu Neurostimulation System |
| Si-Bone, INC. | $919.74 | 2024 | |
| Spinal Simplicity, LLC | $585.76 | 2022-2025 | Ha Minuteman G3-R |
| Saluda Medical Americas, INC. | $524.92 | 2024-2025 | Evoke |
| Biotronik Nro, INC. | $483.86 | 2024-2025 | Prospera |
| Globus Medical, INC. | $463.83 | 2025 | Senza |
| Medtronic, INC. | $409.41 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Foundation Fusion Solutions, LLC | $358.08 | 2023-2024 | |
| Painteq LLC | $256.90 | 2022 | |
| Edwards Lifesciences Corporation | $146.03 | 2019 | |
| Averitas Pharma INC. | $141.48 | 2023 | Qutenza |
| Mml US, INC. | $112.75 | 2024 | Reactiv8 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $104.30 | 2022-2023 | Sprint Pns System |
| Tersera Therapeutics LLC | $100.15 | 2022-2024 | Prialt |
| Grt US Holding, INC. | $54.56 | 2022 | |
| Bioventus LLC | $52.42 | 2024-2025 | Xcell, Exogen Ultrasound Bone Healing System |
| Stryker Corporation | $50.59 | 2024 | Scopis Ent |
| Genzyme Corporation | $44.69 | 2024-2025 | |
| Grifols USA, LLC | $39.47 | 2024-2025 | Prolastin-C Liquid |
| Collegium Pharmaceutical, INC. | $37.10 | 2022 | |
| Innovation Technologies INC | $37.02 | 2023 | Irrisept |
| Relievant Medsystems, INC. | $34.35 | 2022 | |
| Avanos Medical | $31.83 | 2021-2022 | |
| Titan Surgical Group, LLC | $31.11 | 2024 | |
| Abbvie INC. | $30.80 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $30.58 | 2025 | Fasenra |
| Jazz Pharmaceuticals INC. | $30.47 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $23.96 | 2025 | |
| Scilex Pharmaceuticals INC. | $22.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.03 | 2022 | |
| Melinta Therapeutics, LLC | $13.91 | 2024 | Kimyrsa, Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Neuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.